Loading
A phase 2 trial of sacituzumab tirumotecan in lung cancer, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, not yet recruiting.
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis is a phase 2, interventional study registered as NCT07545213 by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, with a registry enrolment figure of 27 participants, started 2026-04-20 and due to reach its primary completion in 2028-02-15. Interventions recorded: SKB264. Conditions listed: Non-small Cell Lung Cancer; EGFR Mutant Advanced Non-small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: "Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) that is locally advanced (stage IIIB/IIIC) or metastatic (stage IV) and not amenable to curative surgery and/or curative radiotherapy (with or without concurrent chemotherapy), according to the IASLC 9th edition lung cancer". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Sacituzumab tirumotecan, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/